These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
252 related articles for article (PubMed ID: 30927375)
1. Dried blood samples can support monitoring of infliximab concentrations in patients with inflammatory bowel disease: A clinical validation. Berends SE; D'Haens GRAM; Schaap T; de Vries A; Rispens T; Bloem K; Mathôt RAA Br J Clin Pharmacol; 2019 Jul; 85(7):1544-1551. PubMed ID: 30927375 [TBL] [Abstract][Full Text] [Related]
2. Predictors of Infliximab Trough Concentrations in Inflammatory Bowel Disease Patients Using a Repeated-Measures Design. Santacana E; Rodríguez-Alonso L; Padullés A; Guardiola J; Bas J; Rodríguez-Moranta F; Serra K; Morandeira F; Colom H; Padullés N Ther Drug Monit; 2020 Feb; 42(1):102-110. PubMed ID: 31283556 [TBL] [Abstract][Full Text] [Related]
3. A Mobile Infliximab Dosing Calculator for Therapy Optimization in Inflammatory Bowel Disease. Piester T; Frymoyer A; Christofferson M; Yu H; Bass D; Park KT Inflamm Bowel Dis; 2018 Jan; 24(2):227-234. PubMed ID: 29361094 [TBL] [Abstract][Full Text] [Related]
4. Population pharmacokinetics of infliximab in patients with inflammatory bowel disease: potential implications for dosing in clinical practice. Buurman DJ; Maurer JM; Keizer RJ; Kosterink JG; Dijkstra G Aliment Pharmacol Ther; 2015 Sep; 42(5):529-39. PubMed ID: 26113313 [TBL] [Abstract][Full Text] [Related]
5. Forecasted infliximab concentrations during induction predict time to remission and sustained disease control of inflammatory bowel disease. Vermeire S; Dubinsky MC; Rabizadeh S; Panetta JC; Spencer EA; Dreesen E; D'Haens G; Dervieux T; Laharie D Clin Res Hepatol Gastroenterol; 2024 Jun; 48(6):102374. PubMed ID: 38750934 [TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic Dashboard-Recommended Dosing Is Different than Standard of Care Dosing in Infliximab-Treated Pediatric IBD Patients. Dubinsky MC; Phan BL; Singh N; Rabizadeh S; Mould DR AAPS J; 2017 Jan; 19(1):215-222. PubMed ID: 27739008 [TBL] [Abstract][Full Text] [Related]
7. Infliximab in paediatric inflammatory bowel disease: External evaluation of population pharmacokinetic models. Heikal OS; van Rheenen PF; Touw DJ; Kosterink JGW; Maurer M; Koomen JV; Chelle P; Mian P Br J Clin Pharmacol; 2024 Sep; 90(9):2200-2214. PubMed ID: 38845210 [TBL] [Abstract][Full Text] [Related]
8. Evaluating an easy sampling method using dried blood spots to determine vedolizumab concentrations. Bian S; Van den Berghe N; Vandersmissen L; Tops S; Vermeire S; Ferrante M; Gils A; Thomas D J Pharm Biomed Anal; 2020 Jun; 185():113224. PubMed ID: 32151929 [TBL] [Abstract][Full Text] [Related]
9. Clinical Validation of a Capillary Blood Home-Based Self-Sampling Technique for Monitoring of Infliximab, Vedolizumab, and C-Reactive Protein Concentrations in Patients With Inflammatory Bowel Disease. Otten AT; van der Meulen HH; Steenhuis M; Loeff FC; Touw DJ; Kosterink JGW; Frijlink HW; Rispens T; Dijkstra G; Visschedijk MC; Bourgonje AR Inflamm Bowel Dis; 2024 Mar; 30(3):325-335. PubMed ID: 37265165 [TBL] [Abstract][Full Text] [Related]
10. New steps in infliximab therapeutic drug monitoring in patients with inflammatory bowel diseases. Nemoz B; Ternant D; Bailly S; Gautier-Veyret E; Jourdil JF; Bonaz B; Stanke-Labesque F Br J Clin Pharmacol; 2019 Apr; 85(4):722-728. PubMed ID: 30575085 [TBL] [Abstract][Full Text] [Related]
11. Infliximab trough levels are decreasing over time in patients with inflammatory bowel disease on maintenance treatment with infliximab. Orfanoudaki E; Gazouli M; Foteinogiannopoulou K; Theodoraki E; Legaki E; Romanos I; Mouzas I; Koutroubakis IE Eur J Gastroenterol Hepatol; 2019 Feb; 31(2):187-191. PubMed ID: 30543573 [TBL] [Abstract][Full Text] [Related]
12. Optimization of infliximab therapy in inflammatory bowel disease using a dashboard approach-an Indian experience. Dave MB; Dherai AJ; Desai DC; Mould DR; Ashavaid TF Eur J Clin Pharmacol; 2021 Jan; 77(1):55-62. PubMed ID: 32803288 [TBL] [Abstract][Full Text] [Related]
13. Infliximab Level Between Venous and Capillary Blood Using Novel Device Strongly Correlate in Paediatric Inflammatory Bowel Disease Patients. Zijlstra M; Jongsma MME; de Vries A; Schaap T; Bloem K; de Ridder L J Pediatr Gastroenterol Nutr; 2021 Jan; 72(1):56-60. PubMed ID: 32804907 [TBL] [Abstract][Full Text] [Related]
14. The Utility of Infliximab Therapeutic Drug Monitoring among Patients with Inflammatory Bowel Disease and Concerns for Loss of Response: A Retrospective Analysis of a Real-World Experience. Mitchell RA; Shuster C; Shahidi N; Galorport C; DeMarco ML; Rosenfeld G; Enns RA; Bressler B Can J Gastroenterol Hepatol; 2016; 2016():5203898. PubMed ID: 27957480 [No Abstract] [Full Text] [Related]
15. Improved Population Pharmacokinetic Model for Predicting Optimized Infliximab Exposure in Pediatric Inflammatory Bowel Disease. Bauman LE; Xiong Y; Mizuno T; Minar P; Fukuda T; Dong M; Rosen MJ; Vinks AA Inflamm Bowel Dis; 2020 Feb; 26(3):429-439. PubMed ID: 31287855 [TBL] [Abstract][Full Text] [Related]
16. Factors associated with reduced infliximab exposure in the treatment of pediatric autoimmune disorders: a cross-sectional prospective convenience sampling study. Funk RS; Shakhnovich V; Cho YK; Polireddy K; Jausurawong T; Gress K; Becker ML Pediatr Rheumatol Online J; 2021 May; 19(1):62. PubMed ID: 33933127 [TBL] [Abstract][Full Text] [Related]
17. Practical Use of Infliximab Concentration Monitoring in Pediatric Crohn Disease. Minar P; Saeed SA; Afreen M; Kim MO; Denson LA J Pediatr Gastroenterol Nutr; 2016 May; 62(5):715-22. PubMed ID: 26551317 [TBL] [Abstract][Full Text] [Related]
18. A Real-life Population Pharmacokinetic Study Reveals Factors Associated with Clearance and Immunogenicity of Infliximab in Inflammatory Bowel Disease. Brandse JF; Mould D; Smeekes O; Ashruf Y; Kuin S; Strik A; van den Brink GR; DʼHaens GR Inflamm Bowel Dis; 2017 Apr; 23(4):650-660. PubMed ID: 28195852 [TBL] [Abstract][Full Text] [Related]
19. Infliximab trough levels: A comparison between the Quantum Blue Infliximab assay and the established ELISA. Lim MH; Aluzaite K; Schultz M; Casey P J Gastroenterol Hepatol; 2020 Aug; 35(8):1302-1306. PubMed ID: 31881552 [TBL] [Abstract][Full Text] [Related]
20. Serum Infliximab Cutoff trough Level Values for Maintaining Hematological Remission in Pediatric Inflammatory Bowel Disease. Choi SY; Kang B; Choe YH Gut Liver; 2019 Sep; 13(5):541-548. PubMed ID: 30970435 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]